Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.
Identifieur interne : 000225 ( Main/Exploration ); précédent : 000224; suivant : 000226Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.
Auteurs : Olga S. Latinovic [États-Unis] ; Lauren M. Neal [États-Unis] ; Yutaka Tagaya [États-Unis] ; Alonso Heredia [États-Unis] ; Sandra Medina-Moreno [États-Unis] ; Juan C. Zapata [États-Unis] ; Marvin Reitz [États-Unis] ; Joseph Bryant [États-Unis] ; Robert R. Redfield [États-Unis]Source :
- AIDS research and human retroviruses [ 1931-8405 ] ; 2019.
Descripteurs français
- KwdFr :
- Agents antiVIH (pharmacologie), Animaux (MeSH), Antigènes CD34 (métabolisme), Cellules souches hématopoïétiques (virologie), Charge virale (effets des médicaments et des substances chimiques), Humains (MeSH), Infections à VIH (traitement médicamenteux), Lymphocytes T CD4+ (immunologie), Maraviroc (pharmacologie), Modèles animaux de maladie humaine (MeSH), Rapport CD4-CD8 (MeSH), Récepteurs CCR5 (effets des médicaments et des substances chimiques), Sirolimus (pharmacologie), Souris (MeSH), Souris SCID (MeSH), Souris knockout (MeSH), Sous-unité gamma commune aux récepteurs des interleukines (génétique), Transplantation de cellules souches hématopoïétiques (MeSH), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (effets des médicaments et des substances chimiques), Virémie (traitement médicamenteux).
- MESH :
- effets des médicaments et des substances chimiques : Charge virale, Récepteurs CCR5, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- génétique : Sous-unité gamma commune aux récepteurs des interleukines.
- immunologie : Lymphocytes T CD4+.
- métabolisme : Antigènes CD34.
- pharmacologie : Agents antiVIH, Maraviroc, Sirolimus.
- traitement médicamenteux : Infections à VIH, Virémie.
- virologie : Cellules souches hématopoïétiques.
- Animaux, Humains, Modèles animaux de maladie humaine, Rapport CD4-CD8, Souris, Souris SCID, Souris knockout, Transplantation de cellules souches hématopoïétiques.
English descriptors
- KwdEn :
- Animals (MeSH), Anti-HIV Agents (pharmacology), Antigens, CD34 (metabolism), CD4-CD8 Ratio (MeSH), CD4-Positive T-Lymphocytes (immunology), Disease Models, Animal (MeSH), HIV Infections (drug therapy), HIV-1 (drug effects), Hematopoietic Stem Cell Transplantation (MeSH), Hematopoietic Stem Cells (virology), Humans (MeSH), Interleukin Receptor Common gamma Subunit (genetics), Maraviroc (pharmacology), Mice (MeSH), Mice, Knockout (MeSH), Mice, SCID (MeSH), Receptors, CCR5 (drug effects), Sirolimus (pharmacology), Viral Load (drug effects), Viremia (drug therapy).
- MESH :
- chemical , drug effects : Receptors, CCR5.
- chemical , genetics : Interleukin Receptor Common gamma Subunit.
- chemical , metabolism : Antigens, CD34.
- chemical , pharmacology : Anti-HIV Agents, Maraviroc, Sirolimus.
- drug effects : HIV-1, Viral Load.
- drug therapy : HIV Infections, Viremia.
- immunology : CD4-Positive T-Lymphocytes.
- virology : Hematopoietic Stem Cells.
- Animals, CD4-CD8 Ratio, Disease Models, Animal, Hematopoietic Stem Cell Transplantation, Humans, Mice, Mice, Knockout, Mice, SCID.
Abstract
Significant progress has been made in the diagnostics and treatment of AIDS since the discovery of the human immunodeficiency virus type 1 (HIV-1) in 1983. The remarkable effectiveness of combined antiretroviral therapy (cART) is evidenced by mortality reduction, control of peripheral blood viral load, and in a nearly normal quality of HIV patients' lives. Remaining obstacles in treatment and cure are drug toxicities and side effects, viral resistance, persistence of HIV-1 reservoirs on termination of cART treatment, the cost of lifelong antiretroviral therapy, and the stigma associated with taking antiretroviral drugs. As determined by plasma viral RNA and peripheral blood mononuclear cells (PBMC) proviral DNA, we show improved suppression of productive HIV infection in human CD34+ hematopoietic stem cell-engrafted NOD (nonobese diabetic)-SCID (severe combined immunodeficiency)-il2rg-/- (NSG) mice by combined treatment with cART and CCR5 targeting drugs, compared with cART alone, as well as an increased preservation of human CD4+ T cells (defined as CD45+ CD3+ CD4+ cells) and CD4+/CD8+ cell ratios in infected mice. The data also suggest a possible reduction in viral reservoirs. Our data confirm that this animal model is suitable for detection of productive HIV infection, replication, and establishment of viral reservoirs. The data also provide proof of principle for the utility of combining CCR5 targeting drugs, maraviroc and rapamycin, with traditional cART to improve control of viremia and reduce viral reservoirs. This study thus serves as a model for future HIV-1 studies that could lead to the clinical development of new generations of antiretroviral drugs.
DOI: 10.1089/AID.2018.0305
PubMed: 31099257
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Suppression of Active HIV-1 Infection in CD34<sup>+</sup> Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.</title><author><name sortKey="Latinovic, Olga S" sort="Latinovic, Olga S" uniqKey="Latinovic O" first="Olga S" last="Latinovic">Olga S. Latinovic</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>2Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>2Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Neal, Lauren M" sort="Neal, Lauren M" uniqKey="Neal L" first="Lauren M" last="Neal">Lauren M. Neal</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Tagaya, Yutaka" sort="Tagaya, Yutaka" uniqKey="Tagaya Y" first="Yutaka" last="Tagaya">Yutaka Tagaya</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>3School of Medicine, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Heredia, Alonso" sort="Heredia, Alonso" uniqKey="Heredia A" first="Alonso" last="Heredia">Alonso Heredia</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>3School of Medicine, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Medina Moreno, Sandra" sort="Medina Moreno, Sandra" uniqKey="Medina Moreno S" first="Sandra" last="Medina-Moreno">Sandra Medina-Moreno</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Zapata, Juan C" sort="Zapata, Juan C" uniqKey="Zapata J" first="Juan C" last="Zapata">Juan C. Zapata</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Reitz, Marvin" sort="Reitz, Marvin" uniqKey="Reitz M" first="Marvin" last="Reitz">Marvin Reitz</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Bryant, Joseph" sort="Bryant, Joseph" uniqKey="Bryant J" first="Joseph" last="Bryant">Joseph Bryant</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>4Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>4Department of Pathology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Redfield, Robert R" sort="Redfield, Robert R" uniqKey="Redfield R" first="Robert R" last="Redfield">Robert R. Redfield</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>3School of Medicine, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31099257</idno><idno type="pmid">31099257</idno><idno type="doi">10.1089/AID.2018.0305</idno><idno type="wicri:Area/Main/Corpus">000272</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000272</idno><idno type="wicri:Area/Main/Curation">000272</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000272</idno><idno type="wicri:Area/Main/Exploration">000272</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Suppression of Active HIV-1 Infection in CD34<sup>+</sup> Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.</title><author><name sortKey="Latinovic, Olga S" sort="Latinovic, Olga S" uniqKey="Latinovic O" first="Olga S" last="Latinovic">Olga S. Latinovic</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>2Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>2Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Neal, Lauren M" sort="Neal, Lauren M" uniqKey="Neal L" first="Lauren M" last="Neal">Lauren M. Neal</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Tagaya, Yutaka" sort="Tagaya, Yutaka" uniqKey="Tagaya Y" first="Yutaka" last="Tagaya">Yutaka Tagaya</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>3School of Medicine, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Heredia, Alonso" sort="Heredia, Alonso" uniqKey="Heredia A" first="Alonso" last="Heredia">Alonso Heredia</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>3School of Medicine, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Medina Moreno, Sandra" sort="Medina Moreno, Sandra" uniqKey="Medina Moreno S" first="Sandra" last="Medina-Moreno">Sandra Medina-Moreno</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Zapata, Juan C" sort="Zapata, Juan C" uniqKey="Zapata J" first="Juan C" last="Zapata">Juan C. Zapata</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Reitz, Marvin" sort="Reitz, Marvin" uniqKey="Reitz M" first="Marvin" last="Reitz">Marvin Reitz</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Bryant, Joseph" sort="Bryant, Joseph" uniqKey="Bryant J" first="Joseph" last="Bryant">Joseph Bryant</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>4Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>4Department of Pathology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author><author><name sortKey="Redfield, Robert R" sort="Redfield, Robert R" uniqKey="Redfield R" first="Robert R" last="Redfield">Robert R. Redfield</name><affiliation wicri:level="2"><nlm:affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>3School of Medicine, University of Maryland School of Medicine, Baltimore</wicri:cityArea></affiliation></author></analytic><series><title level="j">AIDS research and human retroviruses</title><idno type="eISSN">1931-8405</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Anti-HIV Agents (pharmacology)</term><term>Antigens, CD34 (metabolism)</term><term>CD4-CD8 Ratio (MeSH)</term><term>CD4-Positive T-Lymphocytes (immunology)</term><term>Disease Models, Animal (MeSH)</term><term>HIV Infections (drug therapy)</term><term>HIV-1 (drug effects)</term><term>Hematopoietic Stem Cell Transplantation (MeSH)</term><term>Hematopoietic Stem Cells (virology)</term><term>Humans (MeSH)</term><term>Interleukin Receptor Common gamma Subunit (genetics)</term><term>Maraviroc (pharmacology)</term><term>Mice (MeSH)</term><term>Mice, Knockout (MeSH)</term><term>Mice, SCID (MeSH)</term><term>Receptors, CCR5 (drug effects)</term><term>Sirolimus (pharmacology)</term><term>Viral Load (drug effects)</term><term>Viremia (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (pharmacologie)</term><term>Animaux (MeSH)</term><term>Antigènes CD34 (métabolisme)</term><term>Cellules souches hématopoïétiques (virologie)</term><term>Charge virale (effets des médicaments et des substances chimiques)</term><term>Humains (MeSH)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Lymphocytes T CD4+ (immunologie)</term><term>Maraviroc (pharmacologie)</term><term>Modèles animaux de maladie humaine (MeSH)</term><term>Rapport CD4-CD8 (MeSH)</term><term>Récepteurs CCR5 (effets des médicaments et des substances chimiques)</term><term>Sirolimus (pharmacologie)</term><term>Souris (MeSH)</term><term>Souris SCID (MeSH)</term><term>Souris knockout (MeSH)</term><term>Sous-unité gamma commune aux récepteurs des interleukines (génétique)</term><term>Transplantation de cellules souches hématopoïétiques (MeSH)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (effets des médicaments et des substances chimiques)</term><term>Virémie (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Interleukin Receptor Common gamma Subunit</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD34</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Maraviroc</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Charge virale</term><term>Récepteurs CCR5</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-unité gamma commune aux récepteurs des interleukines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T CD4+</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigènes CD34</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term><term>Maraviroc</term><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term><term>Virémie</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules souches hématopoïétiques</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hematopoietic Stem Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CD4-CD8 Ratio</term><term>Disease Models, Animal</term><term>Hematopoietic Stem Cell Transplantation</term><term>Humans</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, SCID</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Rapport CD4-CD8</term><term>Souris</term><term>Souris SCID</term><term>Souris knockout</term><term>Transplantation de cellules souches hématopoïétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Significant progress has been made in the diagnostics and treatment of AIDS since the discovery of the human immunodeficiency virus type 1 (HIV-1) in 1983. The remarkable effectiveness of combined antiretroviral therapy (cART) is evidenced by mortality reduction, control of peripheral blood viral load, and in a nearly normal quality of HIV patients' lives. Remaining obstacles in treatment and cure are drug toxicities and side effects, viral resistance, persistence of HIV-1 reservoirs on termination of cART treatment, the cost of lifelong antiretroviral therapy, and the stigma associated with taking antiretroviral drugs. As determined by plasma viral RNA and peripheral blood mononuclear cells (PBMC) proviral DNA, we show improved suppression of productive HIV infection in human CD34<sup>+</sup> hematopoietic stem cell-engrafted NOD (nonobese diabetic)-SCID (severe combined immunodeficiency)-il2rg<sup>-/-</sup> (NSG) mice by combined treatment with cART and CCR5 targeting drugs, compared with cART alone, as well as an increased preservation of human CD4<sup>+</sup> T cells (defined as CD45<sup>+</sup> CD3<sup>+</sup> CD4<sup>+</sup> cells) and CD4<sup>+</sup>/CD8<sup>+</sup> cell ratios in infected mice. The data also suggest a possible reduction in viral reservoirs. Our data confirm that this animal model is suitable for detection of productive HIV infection, replication, and establishment of viral reservoirs. The data also provide proof of principle for the utility of combining CCR5 targeting drugs, maraviroc and rapamycin, with traditional cART to improve control of viremia and reduce viral reservoirs. This study thus serves as a model for future HIV-1 studies that could lead to the clinical development of new generations of antiretroviral drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31099257</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-8405</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>08</Month></PubDate></JournalIssue><Title>AIDS research and human retroviruses</Title><ISOAbbreviation>AIDS Res Hum Retroviruses</ISOAbbreviation></Journal><ArticleTitle>Suppression of Active HIV-1 Infection in CD34<sup>+</sup> Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.</ArticleTitle><Pagination><MedlinePgn>718-728</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/AID.2018.0305</ELocationID><Abstract><AbstractText>Significant progress has been made in the diagnostics and treatment of AIDS since the discovery of the human immunodeficiency virus type 1 (HIV-1) in 1983. The remarkable effectiveness of combined antiretroviral therapy (cART) is evidenced by mortality reduction, control of peripheral blood viral load, and in a nearly normal quality of HIV patients' lives. Remaining obstacles in treatment and cure are drug toxicities and side effects, viral resistance, persistence of HIV-1 reservoirs on termination of cART treatment, the cost of lifelong antiretroviral therapy, and the stigma associated with taking antiretroviral drugs. As determined by plasma viral RNA and peripheral blood mononuclear cells (PBMC) proviral DNA, we show improved suppression of productive HIV infection in human CD34<sup>+</sup> hematopoietic stem cell-engrafted NOD (nonobese diabetic)-SCID (severe combined immunodeficiency)-il2rg<sup>-/-</sup> (NSG) mice by combined treatment with cART and CCR5 targeting drugs, compared with cART alone, as well as an increased preservation of human CD4<sup>+</sup> T cells (defined as CD45<sup>+</sup> CD3<sup>+</sup> CD4<sup>+</sup> cells) and CD4<sup>+</sup>/CD8<sup>+</sup> cell ratios in infected mice. The data also suggest a possible reduction in viral reservoirs. Our data confirm that this animal model is suitable for detection of productive HIV infection, replication, and establishment of viral reservoirs. The data also provide proof of principle for the utility of combining CCR5 targeting drugs, maraviroc and rapamycin, with traditional cART to improve control of viremia and reduce viral reservoirs. This study thus serves as a model for future HIV-1 studies that could lead to the clinical development of new generations of antiretroviral drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Latinovic</LastName><ForeName>Olga S</ForeName><Initials>OS</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neal</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagaya</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heredia</LastName><ForeName>Alonso</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina-Moreno</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zapata</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitz</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redfield</LastName><ForeName>Robert R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>1Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3School of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AIDS Res Hum Retroviruses</MedlineTA><NlmUniqueID>8709376</NlmUniqueID><ISSNLinking>0889-2229</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018952">Antigens, CD34</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000592874">CCR5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507942">Il2rg protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053631">Interleukin Receptor Common gamma Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance></Chemical><Chemical><RegistryNumber>MD6P741W8A</RegistryNumber><NameOfSubstance UI="D000077592">Maraviroc</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018952" MajorTopicYN="N">Antigens, CD34</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016516" MajorTopicYN="N">CD4-CD8 Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053631" MajorTopicYN="N">Interleukin Receptor Common gamma Subunit</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077592" MajorTopicYN="N">Maraviroc</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019713" MajorTopicYN="N">Receptors, CCR5</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">HIV-1</Keyword><Keyword MajorTopicYN="Y">HIV-1 persistence</Keyword><Keyword MajorTopicYN="Y">HIV-1 prevention</Keyword><Keyword MajorTopicYN="Y">antiretroviral therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31099257</ArticleId><ArticleId IdType="doi">10.1089/AID.2018.0305</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Latinovic, Olga S" sort="Latinovic, Olga S" uniqKey="Latinovic O" first="Olga S" last="Latinovic">Olga S. Latinovic</name></region><name sortKey="Bryant, Joseph" sort="Bryant, Joseph" uniqKey="Bryant J" first="Joseph" last="Bryant">Joseph Bryant</name><name sortKey="Bryant, Joseph" sort="Bryant, Joseph" uniqKey="Bryant J" first="Joseph" last="Bryant">Joseph Bryant</name><name sortKey="Heredia, Alonso" sort="Heredia, Alonso" uniqKey="Heredia A" first="Alonso" last="Heredia">Alonso Heredia</name><name sortKey="Heredia, Alonso" sort="Heredia, Alonso" uniqKey="Heredia A" first="Alonso" last="Heredia">Alonso Heredia</name><name sortKey="Latinovic, Olga S" sort="Latinovic, Olga S" uniqKey="Latinovic O" first="Olga S" last="Latinovic">Olga S. Latinovic</name><name sortKey="Medina Moreno, Sandra" sort="Medina Moreno, Sandra" uniqKey="Medina Moreno S" first="Sandra" last="Medina-Moreno">Sandra Medina-Moreno</name><name sortKey="Neal, Lauren M" sort="Neal, Lauren M" uniqKey="Neal L" first="Lauren M" last="Neal">Lauren M. Neal</name><name sortKey="Redfield, Robert R" sort="Redfield, Robert R" uniqKey="Redfield R" first="Robert R" last="Redfield">Robert R. Redfield</name><name sortKey="Redfield, Robert R" sort="Redfield, Robert R" uniqKey="Redfield R" first="Robert R" last="Redfield">Robert R. Redfield</name><name sortKey="Reitz, Marvin" sort="Reitz, Marvin" uniqKey="Reitz M" first="Marvin" last="Reitz">Marvin Reitz</name><name sortKey="Tagaya, Yutaka" sort="Tagaya, Yutaka" uniqKey="Tagaya Y" first="Yutaka" last="Tagaya">Yutaka Tagaya</name><name sortKey="Tagaya, Yutaka" sort="Tagaya, Yutaka" uniqKey="Tagaya Y" first="Yutaka" last="Tagaya">Yutaka Tagaya</name><name sortKey="Zapata, Juan C" sort="Zapata, Juan C" uniqKey="Zapata J" first="Juan C" last="Zapata">Juan C. Zapata</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000225 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000225 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31099257
|texte= Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31099257" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |